Predict your next investment

Corporation
HEALTHCARE | Disease Diagnosis
myriad.com

See what CB Insights has to offer

Investments

3

Portfolio Exits

3

Partners & Customers

10

Service Providers

1

About Myriad Genetics

Myriad Genetics is a molecular diagnostic company dedicated to making a difference in patient's lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad offers an array of genetic tests, prognostic tests and personalized medicine tests to help healthcare providers assess a patient's increased cancer risk, disease aggressiveness and optimize efficacy of chemotherapy. Myriad's testing products can provide healthcare providers with information to help make medical management decisions to reduce cancer risk and help make sure specific treatments are tailored for each individual patient. It was founded in 1991 and is based in Salt Lake City, Utah.

Myriad Genetics Headquarters Location

320 Wakara Way

Salt Lake City, Utah, 84108,

United States

801-584-3600

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Myriad Genetics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Myriad Genetics in 2 Expert Collections, including Medical Devices.

M

Medical Devices

295 items

Companies that received PMA from the FDA since 2014. Companies tagged as #FDAPMA

H

Health Monitoring & Diagnostics

76 items

Companies developing companion diagnostics and technology enabling the development of companion diagnostics. Tagged as #CompanionDx

Research containing Myriad Genetics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Myriad Genetics in 2 CB Insights research briefs, most recently on Nov 11, 2020.

Latest Myriad Genetics News

Myriad Genetics Partners with Institut für Hämopathologie Hamburg and Centre Georges-Francois LeClerc to Expand Access to Genetic Testing in Europe

Aug 16, 2022

A Latest expansions represent Myriad’s commitment to growing international lab partner program SALT LAKE CITY, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced two partnerships with the Institut für Hämopathologie Hamburg (HPH) in Hamburg, Germany and the Centre Georges-Francois LeClerc (CGFL) in Dijon, France to expand access to MyChoice® CDx Plus testing. HPH and CGFL join Myriad’s network of partner laboratories to help support equitable patient access to genetic testing in key European markets. Anzeige Basiswert MyChoice CDx Plus is a CE-IVD-marked companion diagnostic test that determines Homologous Recombination Deficiency (HRD) status in women with ovarian cancer. Determining HRD status can help healthcare providers better identify patients who are eligible for PARP inhibitor therapy. In Hamburg, Myriad will license and provide MyChoice CDx Plus technology to HPH, which will perform testing in its lab, producing a report based on Myriad’s proprietary Genomic Instability Score (GIS) and homologous recombination repair genes, including BRCA1 and BRCA2. In France, Myriad will license its MyChoice CDx Plus technology to CGFL to perform the test in its lab for the generation of Myriad’s proprietary GIS alongside their tumor BRCA test offering. "Patients and their providers need a timely set of comprehensive, data-driven answers to help them manage disease at the very start,” said Nicole Lambert, Chief Operating Officer, Myriad Genetics. "Through our collaboration with progressive laboratories like HPH and CGFL, we’re able to bring MyChoice CDx Plus testing to global markets and provide critical genetic information that can help healthcare providers guide more personalized and targeted ovarian cancer treatment decisions for patients.” In 2021, Myriad established its first laboratory partnership with the Institute of Pathology at the Universitätsklinikum Marburg in Germany. Myriad plans to continue growing its laboratory partnership program into more countries, and is currently validating a fourth lab in Copenhagen, Denmark. About Myriad Genetics Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. Fast Company named Myriad among the World’s Most Innovative Companies for 2022. For more information, visit www.myriad.com . Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx, Colaris, Colaris AP, MyRisk, Myriad MyRisk, MyRisk Hereditary Cancer, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Precise, FirstGene, Health.Illuminated., RiskScore, Prolaris, GeneSight, and EndoPredict are trademarks or registered trademarks of Myriad Genetics, Inc. © 2022 Myriad Genetics, Inc. All rights reserved. Safe Harbor Statement This press release contains "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company’s partnership with HPH and CGFL to expand access to MyChoice CDx Plus testing, and the company’s plans to continue growing its laboratory partnership program into more countries, These "forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to a number of known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such risks and uncertainties are described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 25, 2022, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad disclaims any obligation to publicly update any forward-looking statement, whether as a result of new information, future developments, or otherwise except as required by law. Media Contact:

Myriad Genetics Investments

3 Investments

Myriad Genetics has made 3 investments. Their latest investment was in RainDance Technologies as part of their Series E - II on March 3, 2014.

CBI Logo

Myriad Genetics Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/3/2014

Series E - II

RainDance Technologies

$16.5M

No

10

4/29/2013

Series E

Subscribe to see more

$99M

Subscribe to see more

10

9/9/2011

Debt

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/3/2014

4/29/2013

9/9/2011

Round

Series E - II

Series E

Debt

Company

RainDance Technologies

Subscribe to see more

Subscribe to see more

Amount

$16.5M

$99M

$99M

New?

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

10

10

10

Myriad Genetics Portfolio Exits

3 Portfolio Exits

Myriad Genetics has 3 portfolio exits. Their latest portfolio exit was Myriad Genetics - Autoimmune Unit on May 03, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

5/3/2021

Divestiture

Myriad Genetics - Autoimmune Unit

$99M

6

4/27/2021

Divestiture

Subscribe to see more

$99M

Subscribe to see more

10

1/16/2017

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/3/2021

4/27/2021

1/16/2017

Exit

Divestiture

Divestiture

Acquired

Companies

Myriad Genetics - Autoimmune Unit

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

6

10

10

Myriad Genetics Acquisitions

5 Acquisitions

Myriad Genetics acquired 5 companies. Their latest acquisition was Counsyl on May 29, 2018.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

5/29/2018

Series E+

$99M

$168.2M

Acquired

3

8/4/2016

Series D

Subscribe to see more

$99M

$99M

Subscribe to see more

10

5/31/2016

Grant

Subscribe to see more

$99M

$99M

Subscribe to see more

10

2/5/2014

Series D

Subscribe to see more

$99M

$99M

Subscribe to see more

10

6/17/2011

Series A

Subscribe to see more

$99M

$99M

Subscribe to see more

0

Date

5/29/2018

8/4/2016

5/31/2016

2/5/2014

6/17/2011

Investment Stage

Series E+

Series D

Grant

Series D

Series A

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$168.2M

$99M

$99M

$99M

$99M

Note

Acquired

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

3

10

10

10

0

Myriad Genetics Partners & Customers

10 Partners and customers

Myriad Genetics has 10 strategic partners and customers. Myriad Genetics recently partnered with EPIC Systems on June 6, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

6/24/2022

Partner

United States

1

5/3/2022

Partner

United States

Myriad Genetics Expands Partnership with Intermountain Precision Genomics to Add Liquid Biopsy Therapy Selection Offering to Portfolio of Precise™ Oncology Solutions

SALT LAKE CITY , May 03 , 2022 -- Myriad Genetics , Inc. , , a leader in genetic testing and precision medicine , today announced the expansion of its strategic partnership with Intermountain , a service of Intermountain Healthcare , to add a new liquid biopsy therapy selection test to its growing oncology portfolio .

2

6/16/2021

Vendor

United States

PierianDx : and Intermountain Healthcare Combine Expertise to Advance Myriad Genetics' Tumor Test Offering

`` We are pleased to enhance our partnership with PierianDx to provide comprehensive genomic test results to Myriad Genetics 's cancer testing service , thereby helping to improve outcomes for patients , '' says Lincoln Nadauld , Vice President and Chief of Precision Medicine and Genomics at Intermountain Healthcare .

2

1/13/2021

Partner

United States

Subscribe to see more

Subscribe to see more

10

11/16/2020

Licensee

China

Subscribe to see more

Subscribe to see more

10

Date

6/24/2022

5/3/2022

6/16/2021

1/13/2021

11/16/2020

Type

Partner

Partner

Vendor

Partner

Licensee

Business Partner

Country

United States

United States

United States

United States

China

News Snippet

Myriad Genetics Expands Partnership with Intermountain Precision Genomics to Add Liquid Biopsy Therapy Selection Offering to Portfolio of Precise™ Oncology Solutions

SALT LAKE CITY , May 03 , 2022 -- Myriad Genetics , Inc. , , a leader in genetic testing and precision medicine , today announced the expansion of its strategic partnership with Intermountain , a service of Intermountain Healthcare , to add a new liquid biopsy therapy selection test to its growing oncology portfolio .

PierianDx : and Intermountain Healthcare Combine Expertise to Advance Myriad Genetics' Tumor Test Offering

`` We are pleased to enhance our partnership with PierianDx to provide comprehensive genomic test results to Myriad Genetics 's cancer testing service , thereby helping to improve outcomes for patients , '' says Lincoln Nadauld , Vice President and Chief of Precision Medicine and Genomics at Intermountain Healthcare .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

2

2

10

10

Myriad Genetics Service Providers

1 Service Provider

Myriad Genetics has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Acquired

Investment Bank

Financial Advisor

Service Provider

Associated Rounds

Acquired

Provider Type

Investment Bank

Service Type

Financial Advisor

Partnership data by VentureSource

Myriad Genetics Team

21 Team Members

Myriad Genetics has 21 team members, including current Chief Executive Officer, President, Paul J. Diaz.

Name

Work History

Title

Status

Dennis B. Farrar

Founder

Current

Kevin B Kimberlin

Founder

Current

Paul J. Diaz

Cressey & Company, Kindred Healthcare, and Mariner Health Care

Chief Executive Officer, President

Current

Bryan Riggsbee

Chief Financial Officer

Current

Nicole Lambert

Chief Operating Officer

Current

Name

Dennis B. Farrar

Kevin B Kimberlin

Paul J. Diaz

Bryan Riggsbee

Nicole Lambert

Work History

Cressey & Company, Kindred Healthcare, and Mariner Health Care

Title

Founder

Founder

Chief Executive Officer, President

Chief Financial Officer

Chief Operating Officer

Status

Current

Current

Current

Current

Current

You May Also Like

Perthera Logo
Perthera

Perthera uses AI to analyze patient medical and molecular data to enable hospitals, physicians & advocacy groups to deliver personalized cancer care. The Perthera Platform matches patients to ranked therapeutic options to improve their clinical outcomes and allows patient data access to the key segments in the Precision Oncology market. It was founded in 2012 and is based in McLean, Virginia.

Strata Oncology Logo
Strata Oncology

Strata Oncology is a precision medicine company that provides no-cost tumor sequencing to advanced cancer patients and a portfolio of matching clinical trials.

SimBioSys Logo
SimBioSys

SimBioSys is developing technology for exploring the economy of tumor microenvironments. Integrating the gamut of health data available for a patient, the capabilities within the TumorScope not only provide predictions for treatment outcomes, but provide the mechanism and reason why a treatment will succeed or fail. As a first target, SimBioSys is calibrating the TumorScope for the war on breast cancer.

D
DxTerity Diagnostics

DxTerity Diagnostics is a biotechnology company focused on utilizing the NEAT platform to provide a pathway to incorporate genetic testing and complex gene signatures into routine medical care.

G
GENECAST

GENECAST develops cancer screening kits that can diagnose and monitor cancer through liquid biopsy using its ADPS (Allele-Discriminating Priming System) technology.

I
INDENA SPA

Indena is a company dedicated to the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health-food and cosmetics industries. Indena, a privately owned Italian company, has around 700 employees, including 10% dedicated to full-time research, aims to manage cultivation, manufacturing, and distribution operations in more than 40 countries throughout the world. The key to Indena's success is its research, covering: the screening of medicinal plants for their pharmacological benefits; the identification of new active principles; and the development of extraction and purification systems at the cutting-edge of industrial application. The phyto-chemical research is carried out in Indena's own Research Center in Settala, Italy. Indena also co-operates with the world's most prestigious universities and private research institutions in the biological assessment of safety and effectiveness up to clinical phase I. One of the main strategic objectives of the research is the development of new active principles for pharmaceutical applications. This is also an indispensable base for the health-food and cosmetics industries. In the pharmaceutical sector Indena is currently focusing on the development of anti-cancer treatments, following the successes of paclitaxel, as well as on anti-microbial and on anti-viral drugs. Also under study are active principles for the treatment of pathologies and dysfunction of the central nervous system, such as depression, anxiety, impotence, sleep disorders, and algesia. Today Indena is also concentrating its efforts on the industrial production of high-quality standardised active principles derived from plants, which are important ingredients in health food products. In fact, the company produces standardised extracts from edible plants that are traditionally recognised as having therapeutic properties, as well as from plants that have proven pharmacological value. Indena's research and production activities are particularly attentive to plant-based principles that have anti-oxidant properties and are effective in preventing damage caused by free radicals. Backed by over 80 years of botanical experience, the Italian company has developed a plantation network, managed by experts, to supply its research and production centers with officinal plants, while at the same time ensuring bio-diversity and protecting the ecosystem balance from uncontrolled harvesting. Today more than 60% of the raw material used in the manufacturing process comes from cultivation. Indena's decades-long global presence in the plant extraction industry is a guarantee of its in-depth knowledge and understanding of the business, market trends and legal considerations, through constant communication and interaction between the company's experts and the major international regulatory authorities such as WHO, EMEA, and ESCOP, and main pharmacopoeias.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.